Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.43 |
| ▸ | AKT1 | P31749 | 3/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | AGER | Q15109 | 3/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | CETP | P11597 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10207431 | 0.89 | HSD11B1 (0.56) | HSD11B1JAK2JAK1HDAC3HDAC1 | |
| SCHEMBL27884072 | 0.87 | AGER (0.54) | HSD11B1JAK2JAK1HDAC3HDAC1 | |
| SCHEMBL31644520 | 0.86 | HSD11B1 (0.50) | HSD11B1JAK2JAK1HDAC3HDAC1 | |
| SCHEMBL18173247 | 0.86 | HSD11B1 (0.43) | HSD11B1HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL14675151 | 0.86 | HSD11B1 (0.53) | HSD11B1JAK2JAK1HDAC3HDAC1 | |
| SCHEMBL14675152 | 0.86 | HSD11B1 (0.53) | HSD11B1JAK2JAK1HDAC3HDAC1 | |
| SCHEMBL28019674 | 0.85 | CCR5 (0.47) | OPRM1AGERMTNR1ACHRM2CHRM3 | |
| SCHEMBL29173108 | 0.85 | HSD11B1 (0.53) | HSD11B1JAK2JAK1HDAC3HDAC1 | |
| SCHEMBL12679107 | 0.85 | HSD11B1 (0.53) | HSD11B1JAK2JAK1HDAC3HDAC1 | |
| Formic Acid SCHEMBL28071336 | 0.85 | HSD11B1 (0.53) | HSD11B1JAK2JAK1HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466808-B2 | Aminopyridine derivatives and their use as selective ALK-2 inhibitors | NOVARTIS AG (CH) | 2025-11-11 | — | — | US | disclosed |
| EP-4442317-A2 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | Novartis AG (CH) | 2024-10-09 | — | — | EP | disclosed |
| EP-3971177-B1 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | NOVARTIS AG (CH) | 2024-06-26 | — | — | EP | disclosed |
| US-20230027752-A1 | OPIOID RECEPTOR AGONIST, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | FUDAN UNIVERSITY (CN) | 2023-01-26 | — | — | US | disclosed |
| EP-3971177-A1 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | Novartis AG (CH) | 2022-03-23 | — | — | EP | disclosed |
| EP-3487851-B1 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | NOVARTIS AG (CH) | 2021-10-20 | — | — | EP | disclosed |
| US-20210155606-A1 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | NOVARTIS AG (CH) | 2021-05-27 | — | — | US | disclosed |
| US-10947218-B2 | Aminopyridine derivatives and their use as selective ALK-2 inhibitors | NOVARTIS AG (CH) | 2021-03-16 | — | — | US | disclosed |
| US-20200299265-A1 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD (CN) | 2020-09-24 | — | — | US | disclosed |
| US-10710980-B2 | Aminopyridine derivatives and their use as selective ALK-2 inhibitors | NOVARTIS AG (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190161474-A1 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD (CN) | 2019-05-30 | — | — | US | disclosed |
| US-20130034495-A1 | ISOTOPOLOGUES OF 4-[9-(TETRAHYDRO-FURAN-3-YL)-8-(2,4,6-TRIFLUORO-PHENYLAMINO)-9H-PURIN-2-YLAMINO]-CYCLOHEXAN-1-OL | SIGNAL PHARMACEUTICALS, LLC | 2013-02-07 | — | — | US | disclosed |
| US-20130034495-A1 | ISOTOPOLOGUES OF 4-[9-(TETRAHYDRO-FURAN-3-YL)-8-(2,4,6-TRIFLUORO-PHENYLAMINO)-9H-PURIN-2-YLAMINO]-CYCLOHEXAN-1-OL | SIGNAL PHARMACEUTICALS, LLC | 2013-02-07 | — | — | US | disclosed |
| US-20130034495-A1 | ISOTOPOLOGUES OF 4-[9-(TETRAHYDRO-FURAN-3-YL)-8-(2,4,6-TRIFLUORO-PHENYLAMINO)-9H-PURIN-2-YLAMINO]-CYCLOHEXAN-1-OL | SIGNAL PHARMACEUTICALS, LLC | 2013-02-07 | — | — | US | disclosed |
| WO-2011071491-A1 | ISOTOPOLOGUES OF 4-[9-(TETRAHYDRO-FURAN-3-YL)-8-(2, 4, 6- TRIFLUORO-PHENYLAMINO)-9H-PURIN-2-YLAMINO]-CYCLOHEXAN-1-OL | SIGNAL PHARMACEUTICALS, LLC (US) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011071491-A1 | ISOTOPOLOGUES OF 4-[9-(TETRAHYDRO-FURAN-3-YL)-8-(2, 4, 6- TRIFLUORO-PHENYLAMINO)-9H-PURIN-2-YLAMINO]-CYCLOHEXAN-1-OL | SIGNAL PHARMACEUTICALS, LLC (US) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10710980-B2 | Aminopyridine derivatives and their use as selective ALK-2 inhibitors | ALK, ACVR2B, ACVR1B | HSD11B1 3302/4885JAK2 624/4885JAK1 803/4885 |
| US-12466808-B2 | Aminopyridine derivatives and their use as selective ALK-2 inhibitors | ALK, ACVR1, ACVR1B | HSD11B1 2740/4885JAK2 664/4885JAK1 561/4885 |
| US-10947218-B2 | Aminopyridine derivatives and their use as selective ALK-2 inhibitors | ALK, ACVR2B, ACVR1B | HSD11B1 3056/4885JAK2 616/4885JAK1 774/4885 |
| US-20200299265-A1 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | ALK, ACVR2B, ACVR1B | HSD11B1 3056/4885JAK2 616/4885JAK1 774/4885 |
| US-20230027752-A1 | OPIOID RECEPTOR AGONIST, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | OPRM1, OPRD1, OPRL1 | HSD11B1 889/4885JAK2 233/4885JAK1 364/4885 |
| US-20190161474-A1 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | ALK, ACVR2B, ACVR1B | HSD11B1 3302/4885JAK2 624/4885JAK1 803/4885 |
| US-20130034495-A1 | ISOTOPOLOGUES OF 4-[9-(TETRAHYDRO-FURAN-3-YL)-8-(2,4,6-TRIFLUORO-PHENYLAMINO)-9H-PURIN-2-YLAMINO]-CYCLOHEXAN-1-OL | DHPS, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CPT1A | HSD11B1 393/4885JAK2 2119/4885JAK1 2118/4885 |
| US-20210155606-A1 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | ALK, ACVR1, ACVR1B | HSD11B1 2740/4885JAK2 664/4885JAK1 561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.